The authors concluded that circulating irisin is dysfunctionally altered in subjects with lower skeletal muscle mass and higher visceral fat [47] which carries implications for any application of irisin as a potential anti-obesity treatment [5, 12]. Here, FNDC5 is linked to obesity due to melanocortin 4 receptor deficiency.